Am. J. Respir. Crit. Care Med., Volume 162, Number 3, September 2000, 1132-1139

Timing of Administration of Anti-VLA-4 Differentiates Airway Hyperresponsiveness in the Central and Peripheral Airways in Mice

ARIHIKO KANEHIRO, KATSUYUKI TAKEDA, ANTHONY JOETHAM, ADRIAN TOMKINSON, TOSHIHIDE IKEMURA, CHARLES G. IRVIN, and ERWIN W. GELFAND

Division of Basic Sciences, Department of Pediatrics and Department of Medicine, National Jewish Medical and Research Center, Denver, Colorado

The development of airway hyperresponsiveness (AHR) is correlated with the infiltration into the lungs of activated eosinophils and T lymphocytes. In large part, influx of eosinophils into the lung is dependent on very late activating antigen-4 (VLA-4) expression. However, the kinetics of eosinophil recruitment and the development of AHR are not fully delineated. Airway function was monitored by changes in lung resistance (RL) and dynamic compliance (Cdyn) to methacholine (MCh) inhalation after anti-VLA-4. After ovalbumin (OVA) sensitization and airway challenge of BALB/c mice, AHR increased as did the number of lung inflammatory cells. Administration of anti-VLA-4 to sensitized mice 2 h before the first (of three) OVA airway challenges significantly prevented changes in RL. Moreover, injection of the antibody from 2 h before the first challenge to 42 h after the last challenge significantly prevented the increases in RL, as well as eosinophil and lymphocyte numbers in the bronchoalveolar lavage fluid (BALF); interleukin-5 (IL-5) and leukotriene concentrations in BALF were also significantly inhibited. Interestingly, treatment with anti-VLA-4 only prevented changes in Cdyn and goblet cell hyperplasia when administered 2 h before the first challenge. These studies demonstrate that the timing of anti-VLA-4 administration can selectively affect pathologic processes that contribute to altered airway function in the central and peripheral airways after allergen challenge.

This article has been cited by other articles:

				A. T. Nials and S. Uddin Mouse models of allergic asthma: acute and chronic allergen challenge Dis. Model. Mech., November 1, 2008; 1(4-5): 213 - 220. [Abstract] [Full Text] [PDF]

				S. R. Barthel, M. W. Johansson, D. M. McNamee, and D. F. Mosher Roles of integrin activation in eosinophil function and the eosinophilic inflammation of asthma J. Leukoc. Biol., January 1, 2008; 83(1): 1 - 12. [Abstract] [Full Text] [PDF]

				A. Hirano, A. Kanehiro, K. Ono, W. Ito, A. Yoshida, C. Okada, H. Nakashima, Y. Tanimoto, M. Kataoka, E. W. Gelfand, et al. Pirfenidone Modulates Airway Responsiveness, Inflammation, and Remodeling after Repeated Challenge Am. J. Respir. Cell Mol. Biol., September 1, 2006; 35(3): 366 - 377. [Abstract] [Full Text] [PDF]

				T. Koya, T. Kodama, K. Takeda, N. Miyahara, E.-S. Yang, C. Taube, A. Joetham, J.-W. Park, A. Dakhama, and E. W. Gelfand Importance of Myeloid Dendritic Cells in Persistent Airway Disease after Repeated Allergen Exposure Am. J. Respir. Crit. Care Med., January 1, 2006; 173(1): 42 - 55. [Abstract] [Full Text] [PDF]

				J. M. Hartney, K. G. Coggins, S. L. Tilley, L. A. Jania, A. K. Lovgren, L. P. Audoly, and B. H. Koller Prostaglandin E2 protects lower airways against bronchoconstriction Am J Physiol Lung Cell Mol Physiol, January 1, 2006; 290(1): L105 - L113. [Abstract] [Full Text] [PDF]

				W. Ito, A. Kanehiro, K. Matsumoto, A. Hirano, K. Ono, H. Maruyama, M. Kataoka, T. Nakamura, E. W. Gelfand, and M. Tanimoto Hepatocyte Growth Factor Attenuates Airway Hyperresponsiveness, Inflammation, and Remodeling Am. J. Respir. Cell Mol. Biol., April 1, 2005; 32(4): 268 - 280. [Abstract] [Full Text] [PDF]

				K. Takeshita, T. Yamasaki, S. Akira, F. Gantner, and K. B. Bacon Essential role of MHC II-independent CD4+ T cells, IL-4 and STAT6 in contact hypersensitivity induced by fluorescein isothiocyanate in the mouse Int. Immunol., May 1, 2004; 16(5): 685 - 695. [Abstract] [Full Text] [PDF]

				C. Taube, C. Duez, Z.-H. Cui, K. Takeda, Y.-H. Rha, J.-W. Park, A. Balhorn, D. D. Donaldson, A. Dakhama, and E. W. Gelfand The Role of IL-13 in Established Allergic Airway Disease J. Immunol., December 1, 2002; 169(11): 6482 - 6489. [Abstract] [Full Text] [PDF]

				A. Kanehiro, M. Lahn, M. J. Makela, A. Dakhama, A. Joetham, Y.-H. Rha, W. Born, and E. W. Gelfand Requirement for the p75 TNF-{alpha} Receptor 2 in the Regulation of Airway Hyperresponsiveness by {gamma}{delta} T Cells J. Immunol., October 15, 2002; 169(8): 4190 - 4197. [Abstract] [Full Text] [PDF]

				E. Kudlacz, C. Whitney, C. Andresen, A. Duplantier, G. Beckius, L. Chupak, A. Klein, K. Kraus, and A. Milici Pulmonary Eosinophilia in a Murine Model of Allergic Inflammation Is Attenuated by Small Molecule alpha 4beta 1 Antagonists J. Pharmacol. Exp. Ther., May 1, 2002; 301(2): 747 - 752. [Abstract] [Full Text] [PDF]

				A. Dakhama, A. Kanehiro, M. J. Makela, J. E. Loader, G. L. Larsen, and E. W. Gelfand Regulation of Airway Hyperresponsiveness by Calcitonin Gene-related Peptide in Allergen Sensitized and Challenged Mice Am. J. Respir. Crit. Care Med., April 15, 2002; 165(8): 1137 - 1144. [Abstract] [Full Text] [PDF]

				M. J. TOBIN Asthma, Airway Biology, and Allergic Rhinitis in AJRCCM 2000 Am. J. Respir. Crit. Care Med., November 1, 2001; 164(9): 1559 - 1580. [Full Text] [PDF]

				A. KANEHIRO, T. IKEMURA, M. J. MÄKELÄ, M. LAHN, A. JOETHAM, A. DAKHAMA, and E. W. GELFAND Inhibition of Phosphodiesterase 4 Attenuates Airway Hyperresponsiveness and Airway Inflammation in a Model of Secondary Allergen Challenge Am. J. Respir. Crit. Care Med., January 1, 2001; 163(1): 173 - 184. [Abstract] [Full Text]